Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Next Previous
X
Search
Trial Profile

Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Artesunate/amodiaquine (Primary) ; Artesunate/pyronaridine (Primary) ; Daclatasvir/sofosbuvir (Primary) ; Favipiravir (Primary) ; Nitazoxanide (Primary) ; Paracetamol
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Shin Poong Pharmaceutical

    • Most Recent Events

    • 16 Sep 2021 Status changed from recruiting to completed.
    • 17 Dec 2020 Planned End Date changed from 1 Jan 2021 to 1 Oct 2021.
    • 17 Dec 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top